Genzyme Corporation

A→Z catalog of Genzyme

A

• Aldurazyme — Laronidase (enzyme replacement) — Mucopolysaccharidosis I (Hurler, Hurler-Scheie, Scheie syndromes) — 0.58 mg/kg IV weekly.

• Aubagio — Teriflunomide — Relapsing multiple sclerosis — 14 mg PO daily.

• Ataluren (Translarna, EU) — Ataluren — Duchenne muscular dystrophy (nonsense mutation) — 40 mg/kg/day PO in 3 divided doses.

B

• Bridion (regional co-distribution) — Sugammadex.

• Bone health supplements (regional Genzyme legacy).

C

• Caprelsa — Vandetanib — Medullary thyroid carcinoma — 300 mg daily.

• Cerezyme — Imiglucerase (enzyme replacement) — Gaucher disease type 1 & 3 — 60 U/kg IV q2w.

• Cerdelga — Eliglustat — Gaucher disease type 1 (substrate reduction therapy) — 84 mg PO BID.

• Campath (legacy, now marketed by Sanofi as Lemtrada).

D

• Dupixent (co-developed with Regeneron, Sanofi Genzyme markets worldwide) — Dupilumab — Atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo nodularis — SC 300 mg q2w (indication-dependent).

E

• Elaprase (distribution in Japan/regions) — Idursulfase — MPS II (Hunter syndrome).

• Enzyme replacement therapies (portfolio includes imiglucerase, alglucosidase alfa, laronidase, galsulfase, etc.).

F

• Fabrazyme — Agalsidase beta (enzyme replacement) — Fabry disease — 1 mg/kg IV q2w.

• Fluorouracil legacy oncology generics (regional).

G

• Gazyva (Roche drug, not Genzyme).

• Gaucher ERTs (Cerezyme, Cerdelga, Zavesca).

H

• Hematology legacy brands — supportive therapies in rare anemias.

I

• Imiglucerase — see Cerezyme.

• Immunology portfolio — Dupixent, Kevzara (co-market).

J

• Jejunal enzyme therapies (nutrition lines, regional).

K

• Kevzara — Sarilumab — RA — 200 mg SC q2w.

• Kynamro — Mipomersen — Homozygous familial hypercholesterolemia (limited use, US/EU access programs) — 200 mg SC weekly.

L

• Lemtrada — Alemtuzumab — Relapsing MS (previously Campath in oncology) — IV infusion courses: 12 mg daily ×5d, then ×3d one year later.

• Laronidase — see Aldurazyme.

M

• Myozyme — Alglucosidase alfa (enzyme replacement) — Pompe disease (infantile & late onset) — 20 mg/kg IV q2w.

• Mavenclad (Sanofi MS portfolio, not Genzyme origin but marketed together).

N

• Nascobal (regional) — Cyanocobalamin nasal spray — B12 deficiency — 500 mcg intranasally weekly.

O

• Oncology legacy drugs (Caprelsa, Campath/Lemtrada, Kynamro, etc.).

P

• Plavix (co-marketed Sanofi, not Genzyme origin).

• Praluent (co-market with Regeneron) — Alirocumab — Hypercholesterolemia — 75–150 mg SC q2w.

Q

• Quinapril generics (regional).

R

• Renvela — Sevelamer carbonate — Hyperphosphatemia in CKD — 800–1600 mg TID with meals.

• Renagel — Sevelamer hydrochloride — Same indication.

• Rare disease enzyme therapies — see above.

S

• Sarilumab (Kevzara) — see K.

• Sanofi oncology immunology integration brands.

T

• Thymoglobulin — Antithymocyte globulin (rabbit) — Transplant rejection prophylaxis/treatment — 1.5 mg/kg/day IV ×4–7 days.

• Translarna — see A.

U

• Umgatox (regional nutrition lines).

V

• Vimizim — Elosulfase alfa (enzyme replacement) — MPS IVA (Morquio A) — 2 mg/kg IV weekly.

• Visudyne (regional rights, now mostly Novartis/Roche).

W

• Winrho SDF — Rho(D) immune globulin IV/IM — ITP, Rh-incompatibility prophylaxis — 250–300 mcg IM.

X

• Xenpozyme — Olipudase alfa — Non-CNS ASMD (Niemann-Pick disease types A/B) — IV q2w, titrated to 3 mg/kg.

Y

• Yescarta (not Genzyme, Gilead/Kite).

Z

• Zavesca — Miglustat — Substrate reduction therapy for Gaucher type 1, Niemann-Pick C — 100 mg PO TID.

• Zarxio biosimilars (co-distribution).